Dr. Bin Wu, our Founder and CEO, recently delivered a compelling presentation at the 3rd LNP Immunogenicity and Toxicity Summit in Boston, showcasing Cytodigm’s innovative Cytofinity™ LNP technology. This breakthrough approach replaces PEG-lipid with gangliosides to significantly enhance safety, reduce immunogenicity, and improve nucleic acid delivery.
Why Replace PEG?
PEG is widely used in drug delivery but comes with challenges like immunogenicity and potential anaphylaxis. Alarmingly, 83% of the German population has anti-PEG antibodies, complicating drug development.
Cytodigm’s Ganglioside Solution
Gangliosides, natural glycosphingolipids, offer a safer, non-immunogenic alternative for PEG-lipid. Our Cytofinity™ LNPs incorporate gangliosides instead of PEG-lipid and can encapsulate various nucleic acids while maintaining satisfactory particle sizes and encapsulation efficiencies.
Performance and Advantages
- Ability to target extrahepatic cells, including T-cells and cells in the bone marrow, without complex antibody conjugation.
- Nebulizable for RNA delivery to the lungs, offering unique inhalation capabilities.
- Eliminates PEG-mediated immunogenicity, facilitating repeat dosing.
Innovative Cell Targeting
Cytofinity™ LNPs bind to Siglec receptors for targeted delivery, showing superior performance in targeting hematopoietic stem cells and T-cells, and are paving the way for safer, more effective gene therapies. We’re thrilled about this advancement and its potential impact on the future of medicine.
